Compounds > valsartan
Page last updated: 2024-08-24

valsartan and Recrudescence

valsartan has been researched along with Recrudescence in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (45.00)29.6817
2010's9 (45.00)24.3611
2020's2 (10.00)2.80

Authors

AuthorsStudies
Chen, H; Chen, M; Han, J; Jiang, J; Shu, Z; Sun, Z; Wang, Q; Wu, B; Xia, Q; Zhang, B; Zhao, J; Zheng, L; Zhou, D; Zhuo, C1
Danzi, GB; De Maria, R; Di Tano, G; Loffi, M; Verde, S1
Claggett, BL; Desai, AS; Gong, J; Jhund, PS; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Mueller-Velten, G; Packer, M; Rouleau, JL; Shen, L; Solomon, SD; Swedberg, K; Zile, MR1
Dong, Z; Li, G; Li, L; Liang, Y; Liu, E; Liu, T; Niu, X; Qi, W; Zhao, Z1
Barlera, S; Cappellini, G; Cosmi, F; Disertori, M; Fabbri, G; Favero, C; Franzosi, MG; Latini, R; Maggioni, AP; Moroni, LA; Quintarelli, S; Staszewsky, L1
Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD1
Li, GP; Li, LF; Liang, YZ; Liu, T; Qi, WW; Xu, G; Ye, L1
Corradi, L; Derosa, G; Ferrari, I; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A1
Arnold, JM; Bourgoun, M; Califf, RM; Ghali, JK; Kober, L; McMurray, JJ; Meris, A; Pfeffer, MA; Skali, H; Solomon, SD; Velazquez, EJ; Verma, A1
Barlera, S; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lucci, D; Maggioni, AP; Staszewsky, L; Tognoni, G1
Al-Khatib, SM; Califf, RM; McMurray, JJ; Pfeffer, MA; Piccini, JP; Pieper, K; Solomon, SD; Van de Werf, F; Velazquez, EJ; Zhang, M1
Barlera, S; Cosmi, F; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lombardi, F; Maggioni, AP; Zeni, P1
Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, J; Signorovitch, JE; Solomon, SD; Swedberg, K; Thune, JJ; Velazquez, E1
Barlera, S; Bianconi, L; Disertori, M; Fabbri, G; Favero, C; Franzosi, MG; Latini, R; Lombardi, F; Lucci, D; Maggioni, AP; Quintarelli, S; Staszewsky, L1
Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H1
Delise, P; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Maggioni, AP; Staszewsky, L; Tognoni, G1
Egashira, K; Funakoshi, K; Ihara, Y; Nakano, K; Ohtani, K; Sata, M; Sunagawa, K; Zhao, G1
Ogawa, H; Sakamoto, T; Shintomi, Y; Yoshimura, M1
Ellis, SG1
Brattström, A; Götting, B; Peters, S; Rust, H; Trümmel, M1

Trials

15 trial(s) available for valsartan and Recrudescence

ArticleYear
Sacubitril/Valsartan Can Reduce Atrial Fibrillation Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation.
    Cardiovascular drugs and therapy, 2023, Volume: 37, Issue:3

    Topics: Atrial Fibrillation; Catheter Ablation; Heart Failure; Humans; Recurrence; Treatment Outcome; Valsartan

2023
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
    European journal of heart failure, 2018, Volume: 20, Issue:4

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Europe; Female; Heart Failure; Humans; Male; Middle Aged; Morbidity; Prospective Studies; Recurrence; Stroke Volume; Survival Rate; Tetrazoles; United States; Valsartan

2018
Upstream therapeutic strategies of valsartan and fluvastatin on hypertensive patients with non-permanent atrial fibrillation.
    Cardiovascular therapeutics, 2018, Volume: 36, Issue:6

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Blood Pressure; China; Disease Progression; Female; Fluvastatin; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Valsartan

2018
Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.
    BMC cardiovascular disorders, 2013, Apr-15, Volume: 13

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Double-Blind Method; Electrocardiography; Female; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Incidence; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Telemetry; Tetrazoles; Thromboembolism; Time Factors; Treatment Outcome; Valine; Valsartan; Warfarin

2013
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
    JACC. Heart failure, 2014, Volume: 2, Issue:2

    Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan

2014
Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
    Trials, 2015, Aug-07, Volume: 16

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Blood Pressure; China; Clinical Protocols; Electrocardiography, Ambulatory; Fatty Acids, Monounsaturated; Fluvastatin; Heart Failure; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Myocardial Infarction; Prospective Studies; Recurrence; Research Design; Risk Assessment; Risk Factors; Shock, Cardiogenic; Time Factors; Treatment Outcome; Valsartan

2015
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
    American journal of hypertension, 2008, Volume: 21, Issue:9

    Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Double-Blind Method; Electrocardiography; Female; Humans; Male; Peptide Fragments; Procollagen; Ramipril; Recurrence; Tetrazoles; Valine; Valsartan

2008
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
    JACC. Cardiovascular imaging, 2008, Volume: 1, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Europe; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography; United States; Valine; Valsartan; Ventricular Remodeling

2008
Valsartan for prevention of recurrent atrial fibrillation.
    The New England journal of medicine, 2009, Apr-16, Volume: 360, Issue:16

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Cardiomegaly; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double-Blind Method; Female; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Recurrence; Tetrazoles; Valine; Valsartan

2009
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial.
    European heart journal, 2010, Volume: 31, Issue:2

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Death, Sudden, Cardiac; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Recurrence; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left

2010
Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
    American heart journal, 2010, Volume: 159, Issue:5

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Diuretics; Electrophysiologic Techniques, Cardiac; Female; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Recurrence; Risk Factors; Tetrazoles; Valine; Valsartan

2010
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
    European journal of heart failure, 2011, Volume: 13, Issue:2

    Topics: Age Factors; Aged; Captopril; Cause of Death; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Recurrence; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left

2011
Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
    American heart journal, 2011, Volume: 162, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Incidence; Italy; Male; Prognosis; Prospective Studies; Recurrence; Tetrazoles; Valine; Valsartan

2011
Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2006, Volume: 7, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Double-Blind Method; Echocardiography; Humans; Italy; Prospective Studies; Recurrence; Research Design; Tetrazoles; Valine; Valsartan

2006
Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial.
    The Journal of invasive cardiology, 2001, Volume: 13, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Angiotensin Receptor Antagonists; Antihypertensive Agents; Coronary Disease; Female; Humans; Male; Middle Aged; Recurrence; Stents; Tetrazoles; Valine; Valsartan

2001

Other Studies

5 other study(ies) available for valsartan and Recrudescence

ArticleYear
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions].
    Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:10

    Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care Facilities; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Biphenyl Compounds; Chronic Disease; Continuity of Patient Care; Coronavirus Infections; COVID-19; Delivery of Health Care; Disease Progression; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Pandemics; Pneumonia, Viral; Quarantine; Recurrence; SARS-CoV-2; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Telephone; Tetrazoles; Valsartan; Withholding Treatment

2020
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Journal of the American College of Cardiology, 2006, Feb-21, Volume: 47, Issue:4

    Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan

2006
Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells.
    Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Biomarkers; Blood Pressure; Blood Vessels; Cell Differentiation; Constriction, Pathologic; Iliac Artery; Imidazoles; Inflammation; Inflammation Mediators; Isoenzymes; Macaca fascicularis; Male; Monocytes; Myocytes, Smooth Muscle; NADPH Oxidases; Oxidative Stress; Rabbits; Recurrence; Renin-Angiotensin System; Stem Cells; Stents; Tetrazoles; Tunica Intima; Valine; Valsartan

2006
Successful treatment of refractory angina pectoris due to multivessel coronary spasm with valsartan.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:17

    Topics: Aged; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Coronary Angiography; Coronary Vasospasm; Dose-Response Relationship, Drug; Humans; Male; Recurrence; Tetrazoles; Valine; Valsartan

2007
Do ACE inhibitors or ARBs limit restenosis after stenting? --assimilating the data.
    The Journal of invasive cardiology, 2001, Volume: 13, Issue:2

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Coronary Disease; Humans; Recurrence; Tetrazoles; Valine; Valsartan

2001